Welcome to our dedicated page for Traws Pharma SEC filings (Ticker: TRAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Traws Pharma, Inc. (NASDAQ: TRAW) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Traws’ clinical-stage antiviral programs, financial position, governance and executive compensation, and they complement the company’s press releases.
Through periodic reports such as the Form 10-K and proxy statements, Traws describes its business focus on developing investigational oral small molecule antivirals for respiratory viral diseases, including COVID-19, Long COVID, bird flu and seasonal influenza. The definitive proxy statement (DEF 14A) outlines board structure, incentive compensation plans and matters submitted to stockholders, while also providing context on corporate governance and director elections.
Current reports on Form 8-K, several of which are referenced in the provided data, document material events such as interim clinical data announcements for ratutrelvir, approval to proceed with Phase 2 COVID-19 studies, dosing of the first Phase 2 subjects, quarterly earnings releases, option and restricted stock unit grants to executives, and the appointment of new board members and officers. These filings also confirm that Traws’ common stock is listed on The Nasdaq Stock Market LLC under the symbol TRAW.
Investors and analysts can use this page to review how Traws reports on its clinical progress with ratutrelvir and tivoxavir marboxil, its legacy oncology programs rigosertib and narazaciclib, and its financial results and capital structure. Forms related to executive and director compensation, incentive plans and governance changes provide additional insight into how the company aligns management incentives with its development priorities.
Stock Titan enhances access to these filings by organizing them chronologically and by form type, and by offering AI-powered summaries that explain the key points of lengthy documents such as annual reports, quarterly updates and 8-Ks. This allows users to quickly understand the significance of new filings, track trends in Traws’ disclosures and identify items such as clinical milestones, financing arrangements or changes in leadership that may be important for evaluating TRAW stock.
Traws Pharma discloses a 6.4% stake held by Squadron Master Fund LP and affiliated filers. The Schedule 13G/A (Amendment No. 3) reports that Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn and William Blank each have shared voting and dispositive power over 511,714 shares.
The filing bases the ownership percentage on 7,990,867 shares outstanding as of November 10, 2025, per the issuer's Form 10-Q. Signatures on the amendment are dated 05/15/2026.
Traws Pharma, Inc. reported a first-quarter 2026 net loss of $7.1 million, reversing net income a year earlier, as it ramped investment in its respiratory virus pipeline. Revenue was zero versus $57,000 in 2025, while research and development spending nearly doubled to $4.9 million, driven by work on ratutrelvir, tivoxavir marboxil and TRX01.
General and administrative costs fell to $2.0 million. Cash and cash equivalents were $3.1 million at March 31, 2026, against an accumulated deficit of $647.1 million and a working capital deficit of $7.9 million. Management states there is substantial doubt about the company’s ability to continue as a going concern without new capital.
In April 2026, Traws closed an equity financing with upfront gross proceeds of $10.0 million and issued milestone-based and common warrants that could raise up to an additional $50.0 million if fully exercised. The company also continued a legal arbitration with a former executive and detailed progress across its clinical programs, including Phase 2 development for ratutrelvir and ongoing regulatory interactions for tivoxavir marboxil.
Traws Pharma, Inc. reported Q1 2026 results showing a net loss of $7.1 million, or $0.53 per basic and diluted share, compared with net income of $21.5 million a year earlier, largely reflecting changes in warrant liability and higher R&D spending.
Revenue was $0.0 million versus $57,000 in Q1 2025. Research and development expense rose to $4.9 million from $2.5 million, while general and administrative expense declined to $2.0 million from $2.8 million.
The company highlighted an up to $60 million private investment in public equity, including $10 million received at closing and additional potential proceeds from milestone-based and three-year warrants, which together with existing cash are expected to fund operations, including a human influenza challenge trial for tivoxavir marboxil, into Q1 2027.
Traws Pharma, Inc. files a registration on Form S-3 to permit resale by selling stockholders of up to 35,897,514 shares of its common stock. The shares comprise Initial Shares and shares issuable upon exercise of Pre-Funded Warrants and Series A, B and C Warrants.
The prospectus states the company will not receive proceeds from resales by selling stockholders; the company would receive cash only if the Warrants are exercised for cash. The filing notes 15,150,669 shares outstanding as of April 24, 2026 for table calculations and lists listing on NASDAQ under TRAW.
OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC filed Amendment No. 3 to report beneficial ownership of 1,876,198 Traws Pharma Shares, or 11.9% of the class. This stake includes 1,203,260 Shares held by OrbiMed Private Investments VIII, LP and 672,938 Shares issuable from presently convertible Series C Non-Voting Convertible Preferred Stock.
OPI VIII also holds 96,348 Pre-Funded Warrants, 96,348 2024 Series A Warrants and 2,988,645 2026 Warrants, which are excluded from the 1,876,198-share figure. OrbiMed entities purchased securities in a December 2024 offering and an April 2026 private placement and entered into a support agreement and a registration rights agreement with the issuer.
Traws Pharma, Inc. filed Amendment No. 1 to its Form 10-K for the year ended December 31, 2025 to add Part III information on directors, executive officers, compensation, ownership and related-party matters because a proxy statement will not be filed within 120 days. The amendment does not update prior financial statements or other disclosures.
The filing details board composition, committee memberships, independence determinations, director and executive pay arrangements, equity awards, significant shareholders, related-party R&D and licensing agreements, and auditor fees, while affirming existing governance policies such as the code of conduct and insider trading policy.
Entities affiliated with OrbiMed increased their indirect stake in Traw Pharma through a private placement. OrbiMed Private Investments VIII LP acquired 597,729 shares of common stock at $1.67 per share and Series A, B and C warrants exercisable for up to 2,988,645 shares at $1.673 per share. Following the purchase, indirect holdings reported for common stock rose to 1,203,250 shares. The transactions closed on April 16, 2026, and the reporting entities disclaim beneficial ownership beyond their pecuniary interest.
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on antivirals for respiratory viral diseases, alongside legacy oncology assets. The company’s lead influenza candidate, tivoxavir marboxil (TXM), showed prolonged plasma exposure after a single dose and strong preclinical activity against H5N1 bird flu in multiple animal models.
Regulators have affirmed that clinical data are required for bird flu approval, and the U.S. IND for TXM is on clinical hold over toxicology concerns, which the company is working to address. Traws is prioritizing TXM as a once-monthly oral prophylactic for influenza and as a single-dose treatment for seasonal and H5N1 flu.
Ratutrelvir, an oral 3CL protease inhibitor for COVID-19, completed a 90‑patient Phase 2a study versus PAXLOVID, with reports of fewer adverse events, no viral rebound, and comparable symptom resolution. Oncology programs narazaciclib and rigosertib have completed or near-complete early studies and are now primarily positioned for partnering. Research and development expenses were $12.1 million in 2025 and $12.8 million in 2024.
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on antivirals for respiratory viral diseases, alongside legacy oncology assets. The company’s lead influenza candidate, tivoxavir marboxil (TXM), showed prolonged plasma exposure after a single dose and strong preclinical activity against H5N1 bird flu in multiple animal models.
Regulators have affirmed that clinical data are required for bird flu approval, and the U.S. IND for TXM is on clinical hold over toxicology concerns, which the company is working to address. Traws is prioritizing TXM as a once-monthly oral prophylactic for influenza and as a single-dose treatment for seasonal and H5N1 flu.
Ratutrelvir, an oral 3CL protease inhibitor for COVID-19, completed a 90‑patient Phase 2a study versus PAXLOVID, with reports of fewer adverse events, no viral rebound, and comparable symptom resolution. Oncology programs narazaciclib and rigosertib have completed or near-complete early studies and are now primarily positioned for partnering. Research and development expenses were $12.1 million in 2025 and $12.8 million in 2024.
Traws Pharma reported 2025 results showing a sharp turnaround to net income of $9.2 million, or $0.83 per basic share, compared with a net loss of $166.5 million in 2024, largely reflecting the absence of prior-year acquired R&D expense and a favorable change in warrant liability.
Revenue rose to $2.8 million from $0.2 million, while R&D and G&A expenses were $12.1 million and $8.5 million, respectively. Cash and cash equivalents were $3.8 million as of December 31 2025. The company completed a private financing of up to $60 million, including $10 million upfront and additional milestone-based warrants, which together with existing cash is expected to fund operations, including a Phase 2a human influenza challenge trial for tivoxavir marboxil, into Q1 2027. Traws also highlighted positive Phase 2a topline data for ratutrelvir in COVID-19.
Traws Pharma reported 2025 results showing a sharp turnaround to net income of $9.2 million, or $0.83 per basic share, compared with a net loss of $166.5 million in 2024, largely reflecting the absence of prior-year acquired R&D expense and a favorable change in warrant liability.
Revenue rose to $2.8 million from $0.2 million, while R&D and G&A expenses were $12.1 million and $8.5 million, respectively. Cash and cash equivalents were $3.8 million as of December 31 2025. The company completed a private financing of up to $60 million, including $10 million upfront and additional milestone-based warrants, which together with existing cash is expected to fund operations, including a Phase 2a human influenza challenge trial for tivoxavir marboxil, into Q1 2027. Traws also highlighted positive Phase 2a topline data for ratutrelvir in COVID-19.
Traws Pharma, Inc. entered into a private investment in public equity financing, raising approximately $10 million in upfront gross proceeds and issuing common stock or pre‑funded warrants plus three series of common stock warrants. The warrants could provide up to an additional $50 million in gross proceeds if fully exercised for cash.
The financing is priced at $1.6730 per share (or $1.6630 per pre‑funded warrant) and is intended to fund a Phase 2a human challenge trial for the company’s influenza program in the United Kingdom. Series A, B and C warrants cover up to 29,914,595 shares in total and are exercisable upon specified regulatory, shareholder and market milestones.
Traws Pharma, Inc. entered into a private investment in public equity financing, raising approximately $10 million in upfront gross proceeds and issuing common stock or pre‑funded warrants plus three series of common stock warrants. The warrants could provide up to an additional $50 million in gross proceeds if fully exercised for cash.
The financing is priced at $1.6730 per share (or $1.6630 per pre‑funded warrant) and is intended to fund a Phase 2a human challenge trial for the company’s influenza program in the United Kingdom. Series A, B and C warrants cover up to 29,914,595 shares in total and are exercisable upon specified regulatory, shareholder and market milestones.